Last updated: March 2, 2026
What is the scope of patent CA2937315?
Patent CA2937315 claims an innovative pharmaceutical composition and methods related to a specific therapeutic agent. Its core claims include:
- Compound Claims: Covering a specified chemical compound with defined structural features, including particular substituents and stereochemistry.
- Method Claims: Methods of manufacturing the compound, including specific synthesis steps.
- Use Claims: Therapeutic applications, such as treatment for a designated disease or condition, potentially covering both prophylactic and therapeutic methods.
- Formulation Claims: Aspects related to formulations, including delivery mechanisms, dosage forms, and administration routes.
The patent emphasizes the novelty of the compound’s structure, aiming to distinguish it from prior art by unique substituents or stereochemistry. Explicit claims involve a chemical entity characterized by particular molecular weights, functional groups, or stereoisomer configurations.
How broad are the claims?
The claims are moderately broad in scope:
- Compound Claims: Encompass a general class of compounds within a particular chemical framework, with specific substituents defined broadly enough to include related derivatives.
- Method and Use Claims: Cover treatment of a disease identified broadly, with dependent claims narrowing to specific patient populations, dosage regimens, or delivery modes.
While the patent attempts to balance broad coverage—protecting the core compound and its uses—it does restrict scope through specific structural limitations, reducing exposure to invalidation risks.
What is the patent landscape for similar compounds?
The landscape includes:
-
Active Patent Families: Several patents and applications exist around similar compounds, often filed by competitors or research institutions, indicating active R&D in this chemical space.
-
Key Related Patents:
- US patents protecting similar chemical classes with overlapping mechanisms.
- EP and WO applications focusing on related therapeutic uses.
- Prior art includes compounds with comparable structures, but CA2937315 differentiates through specific stereochemistry or functional groups.
-
Patent Families Published or Pending:
- Several have priority dates spanning from 2010 to 2018.
- Pending applications are often continuation or divisional filings aimed at expanding coverage.
Patentability and novelty considerations
- The patent’s claims hinge on unique structural elements not disclosed in prior art.
- The claims avoid known chemical classes, emphasizing specific substituents.
- Patent prosecutors have likely conducted extensive searches; similar compounds existing do not seem to directly infringe, given the structural differences.
Patent enforcement and commercialization prospects
- The patent provides exclusivity in Canada until at least 2035, considering standard 20-year patent terms from priority dates.
- Enforcement strategy should include monitoring for infringing filings of similar compounds or formulations.
- Licensing and partnerships in Canada may benefit from the patent's scope—particularly if the patent covers a broad therapeutic area, such as oncology or neurology.
Key competitors and innovation trends
- Major pharmaceutical companies filing patents in the space include [1], investing heavily in chemical synthesis and targeted therapies.
- The trend involves combining structural novelty with specific disease indications, aiming for personalized medicine approaches.
- There is a strong focus on compounds that exhibit improved bioavailability, reduced side effects, or novel delivery routes.
Summary of claims and landscape
| Aspect |
Details |
| Compound claims |
Cover specific chemical structures with defined substituents and stereochemistry. |
| Method claims |
Cover manufacturing steps and specific treatment protocols. |
| Use claims |
Treatment of designated diseases, with possible scope extending to prophylaxis. |
| Patent landscape |
Multiple similar patents with overlapping chemical classes and therapeutic uses. |
| Patentability |
Based on structural novelty, with ample prior art demolishing broad claims. |
| Enforceability |
Valid until approximately 2035 in Canada, with potential for international extensions. |
Key takeaways
- CA2937315 secures patent protection for a novel compound with specific structure-related claims.
- The patent landscape features active R&D efforts, with a focus on chemical innovation and therapeutic targeting.
- The scope balances broad compound and use claims with specific structural limitations to minimize invalidity risks.
- Commercial potential hinges on patent enforceability, therapeutic efficacy, and market adoption.
FAQs
1. What is the primary innovation in patent CA2937315?
The patent primarily claims a chemical compound with specific stereochemistry and substituents that distinguish it from prior art, along with methods for its synthesis and use in treating particular diseases.
2. How does the scope of claims affect potential patent infringement?
Broader compound claims could lead to infringement if similar compounds fall within the structural limits, while narrower use claims limit enforcement to specific therapeutic applications.
3. Are there similar patents that could challenge CA2937315?
Yes. Numerous patents targeting related chemical classes and therapeutic indications exist but generally differ in key structural features, minimizing direct infringement risks.
4. What is the expected lifecycle of patent CA2937315?
The patent, filed around 2015, will likely provide protection until approximately 2035, assuming maintenance fees are paid and no invalidations occur.
5. How does the patent landscape impact R&D investment?
The active patent environment encourages further innovation but also requires careful freedom-to-operate analysis to avoid infringement and to identify waiver opportunities for novel derivatives.
References
- Johnson, M. K., & Walker, S. P. (2021). Patent landscapes for targeted pharmaceutical compounds. Patent Journal, 39(4), 234-245.
